Evidence mapPaperPMID 38626459Full record

ReviewChemical reviews2024

Polymeric Nanoparticles for Drug Delivery.

Maximilian A Beach, Umeka Nayanathara, Yanting Gao, Changhe Zhang, Yijun Xiong, Yufu Wang, Georgina K Such

Abstract readReview
In one paragraph

Review in Chemical reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 353 papers.

0numbers the graph read from it
0cells of the map it votes in
353citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

353 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. NO-PDT and chemotherapy: spatiotemporal control to achieve therapeutic synergy.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Review
  19. Article
  20. Article

293 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maximilian A BeachSchool of Chemistry, The University of Melbourne, Parkville, Victoria 3010, Australia.
Umeka NayanatharaSchool of Chemistry, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0002-4872-9736
Yanting GaoSchool of Chemistry, The University of Melbourne, Parkville, Victoria 3010, Australia.
Changhe ZhangSchool of Chemistry, The University of Melbourne, Parkville, Victoria 3010, Australia.
Yijun XiongSchool of Chemistry, The University of Melbourne, Parkville, Victoria 3010, Australia.
Yufu WangSchool of Chemistry, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0009-0002-4984-3263
Georgina K SuchSchool of Chemistry, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0002-2868-5799

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent emergence of nanomedicine has revolutionized the therapeutic landscape and necessitated the creation of more sophisticated drug delivery systems. Polymeric nanoparticles sit at the forefront of numerous promising drug delivery designs, due to their unmatched control over physiochemical properties such as size, shape, architecture, charge, and surface functionality. Furthermore, polymeric nanoparticles have the ability to navigate various biological barriers to precisely target specific sites within the body, encapsulate a diverse range of therapeutic cargo and efficiently release this cargo in response to internal and external stimuli. However, despite these remarkable advantages, the presence of polymeric nanoparticles in wider clinical application is minimal. This review will provide a comprehensive understanding of polymeric nanoparticles as drug delivery vehicles. The biological barriers affecting drug delivery will be outlined first, followed by a comprehensive description of the various nanoparticle designs and preparation methods, beginning with the polymers on which they are based. The review will meticulously explore the current performance of polymeric nanoparticles against a myriad of diseases including cancer, viral and bacterial infections, before finally evaluating the advantages and crucial challenges that will determine their wider clinical potential in the decades to come.

Indexed as

Drug Delivery SystemsNanoparticlesPolymersAnimalsDrug CarriersHumansNeoplasmsDrug CarriersPolymers

Identifiers

PMID38626459
PMCPMC11086401

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.